PNEUMOVAX 23 contains a mixture of inactive parts from 23 of the most common types of pneumococcal bacteria. PNEUMOVAX 23 is a vaccine given to help prevent infections caused by certain types of ...

The decision was influenced by the positive recommendation from the EMA’s Committee for Medicinal Products for Human Use.

Merck sells Vaxneuvance and Pneumovax 23, which had a combined revenue of $1.1 billion in 2023. Merck had hoped its new pneumococcal vaccine Capvaxive would give it a leg-up against Pfizer ...

Pneumovax 23 induces type-specific antibodies that enhance opsonization, phagocytosis, and killing of pneumococci by leukocytes and other phagocytic cells. The levels of antibodies that correlate ...